Dosing & Uses
Dosage Forms & Strengths
injectable SC solution
- 20mg/mL single-dose prefilled syringe
Febrile Neutropenia
Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
20 mg SC once per chemotherapy cycle given at least 24 hr after cytotoxic chemotherapy
Do not administer within 14 days before and <24 hr after administration of chemotherapy
Dosage Modifications
Renal or hepatic impairment
- Pharmacokinetics are unknown
Dosing Considerations
Limitation of use: Not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Safety and efficacy not established
Adverse Effects
>10%
Nausea (51%)
Anemia (15%)
Thrombocytopenia (12%)
Warnings
Contraindications
History of serious allergic reactions to granulocyte stimulating factor (eg, efbemalenograstim alfa, pegfilgrastim, filgrastim)
Cautions
Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture
Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress; discontinue if ARDS confirmed
Serious allergic reactions, including anaphylaxis: Permanently discontinue
Sickle cell crises in patients with sickle cell disorders: Discontinue if sickle cell crisis occurs
Glomerulonephritis: Evaluate and consider dose reduction or interruption if causality is likely
Leukocytosis: WBC counts of 100 × ≥109 /L observed in patients receiving recombinant human granulocyte colony-stimiulating factor (rhG-CSF) products; monitor complete blood count (CBC) count during therapy; discontinue if WBC count exceeds 100 × 109/L
Thrombocytopenia: Monitor platelet counts
Capillary leak syndrome: Monitor symptoms; consider intensive care
Potential for tumor growth
- The G-CSF receptor, through which efbemalenograstim alfa acts, has been found on tumor cell lines
- The possibility exists that efbemalenograstim alfa could act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which it is not approved
Myelodysplasia and myeloid malignancy
- Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer
- Monitor patients with breast and lung cancer using efbemalenograstim alfa in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML
Aortitis
- Aortitis reported in patients receiving rhG-CSF products, occurring as early as the first week after starting therapy
- Manifestations may include generalized signs and symptoms (eg, fever, abdominal pain, malaise, back pain, and increased inflammatory markers [eg, C-reactive protein, WBC count])
- Consider aortitis in patients who develop these signs and symptoms without other known etiology
- Discontinue if aortitis suspected
Nuclear imaging
- Increased hematopoietic activity of bone marrow in response to growth factor therapy associated with transient positive bone imaging changes
- Consider this when interpreting bone imaging results
Pregnancy & Lactation
Pregnancy
Available data regarding use in pregnant females are insufficient to establish drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Published studies data on with exposure to other human G-CSF products have not established an association of G-CSF product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes
Animal studies
- No evidence of reproductive/developmental toxicity occurred in offspring of pregnant rats and rabbits that received cumulative doses of efbemalenograstim alfa ~2.6 and 0.7 times, respectively, the recommended human dose (based on body surface area)
Lactation
Data are unavailable on presence of efbemalenograstim alfa or its metabolite in either human or animal milk, effects on breastfed children, or effects on milk production
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation
Absorption
Peak plasma time
- Cycle 1: 36 hr
- Cycle 3: 24-30 hr
Peak plasma concentration
- Cycle 1: 1,085 ng/mL
- Cycle 3: 525 ng/mL
AUC
- Cycle 1: 54,858 hr⋅ng/mL
- Cycle 3: 26,217 hr⋅ng/mL
Distribution
Vd
- Cycle 1: 18.8 L
- Cycle 3: 40.7 L
Metabolism
Expected to be metabolized into small peptides by catabolic pathways
Elimination
Half-life
- Cycle 1: 35.6 hr
- Cycle 3: 36.9 hr
Clearance
- Cycle 1: 0.36 L/hr
- Cycle 3: 0.76 L/hr
- Neutrophil receptor binding is an important component of efbemalenograstim alfa clearance and is directly related to number of neutrophils
Administration
SC Preparation
Remove from refrigerator (keep prefilled syringe inside carton) at least 30 minutes before administering, to allow product to reach room temperature
Discard any product left at room temperature >48 hr
Inspect visually for particulate matter and discoloration before administration
Solution should appear clear and colorless; discard if discoloration or particulates observed
Do not administer to patients with latex allergy; product contains natural rubber latex, which may cause allergic reactions; needle cap on prefilled syringe contains natural rubber
Prefilled syringe does not bear graduation marks and is intended only to deliver the entire syringe contents (20 mg/mL) for direct administration
SC Administration
Administer SC by a healthcare professional
Administer injection by pinching skin and holding
Inject into abdomen, back or side of upper arms, or thighs
Rotate injection sites
Do not inject into scar tissue or areas that are reddened, inflamed, or swollen
If injecting into abdomen, avoid a 2-inch diameter circle around navel
Once entire dose has been injected, needle safety device will be triggered, pulling needle automatically from skin, and into barrel; entire needle will be covered by needle guard
Storage
Refrigerate at 2-8ºC (36-46ºF) in carton to protect from light
Do not shake
Discard syringes stored at room temperature >48 hr
Do not freeze; discard syringe if frozen
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.